Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Question

Staff  |  Issue: August 2009  |  August 1, 2009

A 72-year-old patient comes in for a routine follow-up visit for osteoarthritis, during which she reports that her right knee has been more swollen and stiff in the past three weeks. The patient is on celecoxib and ranitidine (the patient had an intraarticular injection of her knee six months ago, with marked improvement in knee pain and swelling) and mentions that she has been having abdominal pain and nausea after she takes celecoxib. She has never experienced the celecoxib-associated pain and nausea before.

On examination, the patient was alert and oriented. Her vital signs were normal, her height is 5’7”, her weight is 140 lbs., and she has a body mass index of 21.9. The patient’s head, eye, ear, nose, and throat exam is normal, and there is no lymphadenopathy. Her lungs are clear; her heart has a regular rate and rhythm with no murmurs or friction rubs. The patient exhibits good peripheral pulses, and her abdomen is soft, non-tender, with no mass or hepatosplenomegaly. The patient’s physical examination is remarkable for a large effusion of the right knee.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The physician explains therapeutic options to the patient, including risks and benefits, and performs an aspiration of the right knee and gives a Synvisc injection. The patient is taken off of celecoxib, a new prescription for the pain is prescribed, and the patient is given discharge instructions on post-arthrocentesis care and follow-up.

How would you code this?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Click Here For the Answer.

Share: 

Filed under:Billing/CodingPractice Support Tagged with:BillingCodingOsteoarthritis

Related Articles

    Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

    December 13, 2016

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

    Celecoxib & Cardiovascular Death: NSAID Safety Under Review

    December 7, 2016

    A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

    Celecoxib Is a Safe Treatment for Arthritis

    February 20, 2017

    A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…

    Exercise Therapy Recommended to Manage Knee Osteoarthritis

    July 12, 2016

    The benefits of exercise therapy for individuals with knee osteoarthritis (OA) are well known. The ACR strongly recommends both aquatic exercise and land-based aerobic and resistance exercise for managing knee OA.1 A recent Cochrane systematic review and meta-analysis concluded that high-quality evidence supports the use of exercise to reduce pain and improve physical function and…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences